Real-World Evaluation of the Safety and Effectiveness of Apixaban & Rivaroxaban Lead-in Dosing Compared to Parenteral Lead-in Dosing in the Treatment of Venous Thromboembolism: A Multi-Center Retrospective Cohort Study.
Ghazwa B KorayemOmar A AlshayaNirvana AlnajjarAhad AlawadRand AlotaibiNader Bin SheraimFatemah M HakamiOhud S AlsudyyesRahaf H AlsoghayerLina M AlhushanAsma H QudayrMajed S Al YamiOmar A AlmohammedPublished in: International journal of general medicine (2023)
Parenteral anticoagulation lead-in before starting maintenance of apixaban and rivaroxaban showed a significantly higher risk of bleeding and a trend toward higher VTE recurrence than the DOAC lead-in. This study adds to the evidence supporting the utilization of the DOAC lead-in regimen in treating patients with VTE. Still, larger studies with robust designs are needed to confirm these findings.